Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5
Links:
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…
http://ow.ly/dq6I50Gqhob
06-11-2021
